OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
J Venom Res
Open-access
Aptamers
Open-access
Aptamers 2019
03-04 April 2019, Oxford
Submit a manuscript

By

admin
We are delighted and honoured that Professor Larry Gold will deliver a keynote address at Aptamers 2020. He will also receive a Lifetime Achievement Award on behalf of the International Society on Aptamers (INSOAP) for is pioneering and extraordinary contributions to the field of aptamers and therapeutics. Dr Larry Gold is the Founder and Chairman...
Read More
We are delighted to announce that Dr Nebojsa Janjic will chair Aptamers 2020. Dr Nebojsa Janjic is the Chief Science Officer at SomaLogic. Prior to joining SomaLogic, Dr Janjic was the CSO at Replidyne, Inc, a biotechnology company focusing on the development of small-molecule antibacterial agents. Prior to Replidyne, he was Senior Director of Drug Discovery...
Read More
The INSOAP’s Aptamers meeting has been running at Oxford since 2014, and has attracted attendance from several key scientists in the field, industry researchers, solution providers, and young and emerging researchers. We are now inviting proposals for chairing the 2020 meeting. If you are interested in chairing it, or would like to suggest a chair,...
Read More
Fee Structure Early bird and group discounts are available. Register 3 for the price of 2 until 31 December 2019 (cheapest registration free – Promocode: 3for2)* Register 4 for the price of 3 any time (cheapest registration free – Promocode: 4for3)* Fees apply to payments made on or before the indicated deadlines and not to...
Read More
TAGCyx Biotechnologies Inc. is a drug discovery and development company based in Japan, spun out of Riken Research Institute. We utilizes its proprietary, artificial nucleotide base pair technology invented by Dr. Ichiro Hirao to generate unique DNA aptamer, Xenoligo®, for therapeutic purposes.  Amongst various type of aptamers, the advantage of Xenoligo® are: 1) comprised of DNA,...
Read More
ATDBio was established to provide high quality oligonucleotides to scientists around the world. ATDBio oligonucleotides are used successfully in academic and commercial research in the fields of genetics, genomics, molecular biology, biochemistry, biotechnology and nanotechnology. We supply a wide range of custom-made unmodified and chemically modified oligonucleotides for small and large scale applications. ATDBio specialises in highly...
Read More
RIBOMIC Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies called the RiboART System. RIBOMIC has been promoting the pharmaceutical discovery program in collaboration with Otsuka Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., The University of Tokyo, and some...
Read More
Aptamer Solutions Ltd: Continued success and growth has enabled Aptamer Group to restructure its Scientific Operations team. Increasing interest in the development of aptamers against small molecule targets has led to the formation of a dedicated scientific team. This is in addition to the existing team focused on aptamer generation against larger targets (proteins, viruses,...
Read More
PROTOCOL/METHOD ISSN: 2514-3247 Aptamers (2018), Vol 2, in press Published online: 12 June 2018 Full Text Access  Sladjana Slavkovic and Philip E. Johnson* Department of Chemistry and Centre for Research on Biomolecular Interactions, York University, Toronto, Ontario, Canada, M2R 1A1 *Correspondence to: Philip Johnson, Email: pjohnson@yorku.ca, Tel: 1 416 736 2100 x33119 Received: 31 January 2018...
Read More
We are delighted to announce that Professor Günter Mayer will chair Aptamers 2019.  Professor Mayer is the Professor of Chemical Biology at Life and Medical Sciences Institute (LIMES), Bonn University, Germany, and heads an international team of researchers investigating the use of aptamer technology in understanding biological phenomena and developing nucleic acids as drugs or drug targets...
Read More
1 2 3 19

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases